To establish the optimal concentration of sitagliptin required to inhibit systemic and tumour-localised DPP4 activity, mice bearing ovarian tumours were treated with 25, 50 or 100 mg/kg/day (oral, in food) sitagliptin for two weeks. The gene discussed is DPP4; the disease is neoplasm.